Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A new interdisciplinary Oxford research programme will explore the relationship between metabolism and inflammation in metabolic diseases.

Our group will bring expertise in molecular controls of immune cell function. We will use the state-of-the-art genomic technologies to examine the macrophage-neutrophil cross-talk in obesity and the role of the IRF5 pathway by analysing various adipose tissue depots. - Professor Irina Udalova

Led by Professor Robin Choudhury, of the Radcliffe Department of Medicine, the project goes from big data analysis to find a causal relationship between inflammatory factors and the development of type 2 diabetes and related disorders, to analysis of molecular and cellular mechanisms, to intervention studies.

Professor Irina Udalova, from the Kennedy Institute and a research partner on the project says: "Our group will bring expertise in molecular controls of immune cell function. We have recently demonstrated that modulation of a transcription factor IRF5 impacts on the relative mass of different adipose tissue depots and thus insulin sensitivity in obesity. We will use the state-of-the-art genomic technologies to examine the macrophage-neutrophil cross-talk in obesity and the role of the IRF5 pathway by analysing various adipose tissue depots."

This is one of two projects funded by Novo Nordisk Foundation, which combine the fields of immunology and metabolic research and bring together investigators from Oxford, the University of Copenhagen, Denmark, and the Karolinska Institutet in Sweden.

Obesity, insulin resistance, type 2 diabetes (T2D) and associated cardiovascular disease (CVD) - all metabolic diseases - are an epidemic global health problem. Almost 400 million people worldwide have type 2 diabetes, and total deaths from the condition are anticipated to rise by more than 50% in the next 10 years. Therefore, research that addresses the causes and complications of these diseases and delivers effective treatment for them is of paramount importance.

Professor Choudhury says: "The goal of the programme is to revise the way we regard diabetes spectrum diseases by learning more about the role of inflammation in the pathogenesis of the disease and, in particular, the vascular complications. If successful we may open up new therapeutic possibilities that go beyond merely treating blood sugar and instead target biologically relevant pathways and processes."

Read more here.

Similar stories

Communication at the crossroads of the immune system

In his inaugural article in the Proceedings of the National Academy of Sciences as an NAS member (elected 2021), Prof Mike Dustin and his research team have explained how messages are passed across the immunological synapse. The research could have implications for future vaccine development and immunotherapy treatments.

New drug offers hope for people with hand osteoarthritis

A new study, published in Science Translational Medicine by researchers at the University of Oxford has identified that Talarozole, a drug that is known to increase retinoic acid, was able to prevent osteoarthritis (OA) in disease models.

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

NIHR funding for musculoskeletal and inflammatory disease research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients.

Leducq Foundation grant boosts cardiovascular research

The Leducq Foundation has awarded $7.5 million to researchers at the University of Oxford and their collaborators to advance immunotherapy as a treatment for cardiovascular disease, the leading cause of death in the UK.

MRC funding awarded to Kennedy researchers

Two new projects led by Tal Arnon and Irina Udalova have been awarded Medical Research Council (MRC) funding.